RE:RE:Gibbons say S/P is going no where until Warrants expire!!!! QIPT should get a higher multiple than Apria due to greater growth potential. It's easier to double sales when it's at $100 million than at $1 billion. And as Adapthealth data shows smaller acquistions have more cost synergies than large ones. Also, Apria's ebitda growth has come in part from cost cutting.....
"we streamlined our management structure and further optimized our branch network by reducing our locations open to the public from over 400 to approximately 275 without materially reducing the coverage of our service areas or the quality of our service"
Carlito3311 wrote: It's hard with Apria out there trading at 1x net sales and 5-6x ebitda...makes it tough to warrant a high mulltipe unless there is robust growth. Apria's ipo and valuation has busted up the valuations in this space a bit.